ClinicalTrials.gg
RecruitingNCT07081152RAYONUpdated Mar 23, 2026

Iron Absorption and Losses in Young South African Women Living Without and With Overweight and Obesity

An interventional study of Ferrous sulfate in Obesity, Iron Deficiency and Inflammation, sponsored by Linda Malan. Recruiting at 1 site in South Africa. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by Linda Malan · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
18 Years to 35 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Obesity with a site in South Africa — 9 open to participants now, 12 under way, 5 of them phase 3. Obesity · South Africa.

Planned enrollment
24th of 28
70 · median 825
Started
2025
with 2 others
No phase
5 of 40
2 open now
Primary completion
2027-06
later than 5 of 11 live
Registered
33rd of 40
by date
Lead sponsor
1 of 40
Linda Malan

Among the 40 studies in Obesity with a site in South Africa, this one is the 24th largest by planned enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 with no phase, reaches primary completion later than 5 of the 11 other live ones, and was the 33rd registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 40 studies in Obesity with a site in South Africa are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 35 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Obesity with a site in South Africa, or all of them as a file.
02

Study summary

Young women living with obesity (OB) have a greater risk of developing iron deficiency. Plus, the risk of anemia and/or ID in young women living with overweight (OW) and obesity (OB) is further increased by inadequate dietary intake and/or poor bioavailability of iron, as well as gastrointestinal and menstrual iron losses. It is not certain whether women living with OW/OB can meet their iron requirements from their day-to-day diet.

The aim of this study is to compare iron absorption and losses over a long period between women living with and without OW and OB. Secondary outcomes include iron and inflammation status, as well as dietary iron intake.

Read the detailed description

Adiposity-related inflammation stimulates an increase in secretion of hepcidin hormone thus limiting the absorption of iron and increasing the risk for iron deficiency (ID). In addition, the risk of anemia and/or ID in young women living with overweight (OW) or obesity (OB) is further increased by inadequate dietary intake and/or poor bioavailability of iron, as well as gastrointestinal and menstrual iron losses. Although one study quantified iron losses and absorption in young African women using the stable isotope dilution method the focus was on normal-weight women. Thus, whether women living with OW/OB can meet their iron requirements from their habitual diet remains uncertain.

This is a longitudinal study including an iron absorption study (Phase 1) and a follow-up period (Phase 2) in women living with and without OW and OB.

In phase 1, 70 healthy, mildly- and non-anemic young women living with and without OW or OB will receive a test drink labelled with 15 mg of labelled ferrous sulfate (57Fe) (Visit 1). Fractional iron absorption from the test drink will be determined by measuring the incorporation of the isotopic label into red blood cells 14 days after administration (Visit 2), and will be compared between the two groups. Participants will then undergo a one-year equilibration period. During this time, they will be contacted monthly for an electronically completed, telephonic or in-person health check, chronic medication and supplement use,, blood donation or transfusion, and whether they have fallen pregnant. In addition, they will be asked if they are on a weight-loss diet, a urine pregnancy test done and weight and haemoglobin measured once every 3-4 months. Halfway through the equilibration period we will ask participants not taking hormonal contraceptives (and not intending to do so in phase 2 of the study), to track their menstrual cycle by providing them with a monthly paper- or electronic calendar.

About 1 year after isotope administration, participants will be contacted again and screened (Visit 3) for phase 2 of the study. During this visit, a health and medical history check including the use of proton pump inhibitors,antacids, H2 blockers or iron supplements, contraceptive use and menstruation intensity will be conducted. Then, anthropometric measurements will be performed to determine BMI, and a urine sample collected for pregnancy test. If the participant qualifies to proceed with phase 2, they will be required to consume an antihelminthic dose. Phase 2 of the study will involve 4 visits (Visits 4 to 7), where they will be followed up for 6 months. During this time, blood samples will be drawn every 8 weeks for the determination of isotopic composition. In addition, iron and inflammation status will be assessed. Dietary intake will be assessed using three 24-hour recalls conducted within visits 4, 6 and 7.

Additionally, for willing participants not using hormonal contraceptives and having a regular cycle (26 to 30 days), Visit 4 (or subsequent convenient visit) will be planned to coincide with day 2 of their menstrual phase where 6 ml of blood will be drawn to quantify sex hormones, hepcidin, iron and inflammation status and IL-6. These participants will be invited again during the follicular phase (day 7), early luteal phase (day 18) and late luteal phase (day 23) for additional blood samples. For each of these sampling points, a window period of +/- 1 day will be allowed.

03

Conditions studied

  • Obesity
  • Iron Deficiency
  • Inflammation
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Of African descent
  • of 18.5 to 24.9 kg/m2 for participants living without OW/OB and BMI ≥ 28 kg/m2 for participants living with OW/OB
  • Having low to moderate inflammation-adjusted iron stores (ferritin ≤50 µg/L)
  • Absence of low-grade inflammation (CRP\<2 mg/l) for participants living without OW/OB and presence of low-grade inflammation CRP 2-20 mg/l) for participants living with OW/OB
  • Planning to reside in the study area for at least 2 years

Exclusion criteria

Exclusion Criteria:

  • \< 11 g/dl
  • Treated or self-reported chronic or malabsorptive disorder
  • Current use of chronic anti-inflammatory medication, like or non-steroidal anti-inflammatory medication
  • Pregnancy or planning to become pregnant in the next 2 years
  • Lactation
  • Fear of needles or experiencing vaso-vagal episodes when exposed to blood
  • Difficulty drawing blood due to poor quality veins
  • Blood donation in the past 4 months or plans to donate blood during the study
  • On a weight-loss diet or program or planning to start the same during the study
  • Smoking
  • Unwillingness to stop taking iron and /or vitamin C-containing supplements during phase 1 of the study
  • Regular use of antacids, proton pump inhibitors or H2 blockers

Additional inclusion criteria applicable to phase 2 of the study

  • Labelled with stable iron isotope (tracer) for a minimum of one year
  • Willingness not to start or stop use during the 6 months
  • ≥ 18.5 to 24.9 kg/m2 for participants living without OW/OB and BMI ≥ 28 kg/m2 for participants living with OW/OB

Additional exclusion criteria applicable to phase 2 of the study

- Blood transfusion, intravenous iron infusion, blood donation or significant blood loss during the equilibration period

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Active comparator
    Living without overweight/obesity

    Participants with body mass index between 18 and 24.9 kg/m2

    Other: Ferrous sulfate

  • Experimental
    Living with overweight/obesity

    Participants with body mass index equal to or greater than 28 kg/m2

    Other: Ferrous sulfate

Interventions

  • OtherFerrous sulfate

    All participants will receive a single dose of 15 mg of iron as isotopically prepared ferrous sulfate labelled with 57Fe. The iron dose will be given with ascorbic acid to attain a molar ratio of ascorbic acid:iron of 2:1

06

What researchers measure

Primary outcomes

  1. Iron absorption

    Long-term iron absorption will be determined in, and compared between women living without and with OW/OB in Phase 2 of the study and will be proportional to the change in the concentration of iron isotope 57 in the erythrocyte over time.

    Time frame: Visits 4 (day 373), 5 (day 429), 6 (day 485) and 7 (day 541)

Secondary outcomes

  1. Iron losses

    Long-term iron losses will be determined in, and compared between women living without and with OW/OB in Phase 2 of the study and will be proportional to the change in the absolute amount of iron isotope 57 in the erythrocyte over time.

    Time frame: Visits 4 (day 373), 5 (day 429), 6 (day 485) and 7 (day 541)

  2. Iron balance

    Iron balance will be calculated in and compared between women living without and with OW/OB as the difference between iron absorption and iron losses.

    Time frame: Visits 4 (day 373), 5 (day 429), 6 (day 485) and 7 (day 541)

  3. Fractional iron absorption

    Fractional iron absorption from a single dose of 15 mg of isotopically-labeled iron will be compared between women living without and with OW/OB.

    Time frame: Visit 2 (day 15)

  4. Iron status

    Iron status will be determined by measuring plasma ferritin and soluble transferrin receptor.

    Time frame: Screening (Ferritin only), Visits 1 (day 1), 4 (day 373), day 378, day 389 and day 394], 5 (day 429), 6 (day 485) and 7 (day 541)

  5. Inflammation status

    Inflammation status will be determined by measuring plasma C-reactive protein (CRP) and alpha-1-acid glycoprotein. CRP will also be used to assess the absence or presence of low-grade inflammation at screening for phase 1 and visit 3, using a cut-off of \<2 mg/l and 2-20 mg/l, respectively.

    Time frame: Screening (CRP only), Visit 1 (day 1), 3 (day 366;CRP only), day 378, day 389 and day 394] 4 (day 373), 5 (day 429), 6 (day 485) and 7 (day 541)

  6. Dietary iron intake

    Dietary iron intake will be assessed using 3 x 24 hr recalls within visits 4, 6 and 7.

    Time frame: Visits 4 (day 373), 5 (day 429), 6 (day 485) and 7 (day 541)

  7. Laboratory comparison of measurement of red blood cell isotope concentrations

    Iron isotope concentration measurements will be compared between the laboratories at North-West University and the Swiss Federal Institute of Technology Zurich.

    Time frame: Visit 2 (day 15), 4 (day 373), 5 (day 429), 6 (day 485) and 7 (day 541)

  8. Dietary intake of iron absorption enhancers

    Dietary intake of iron absorption enhancers like vitamin C will be determined using 3 x 24-h recalls questionnaire conducted within the scheduled visit

    Time frame: Visits 4 (day 373), 6 (day 485) and 7 (day 541)

  9. Dietary intake of iron absorption inhibitors

    Dietary intake of iron absorption inhibitors like phytic acid will be determined using 3 x 24-h recalls questionnaire conducted within the scheduled visit

    Time frame: Visits 4 (day 373), 6 (day 485) and 7 (day 541)

  10. Body fat percentage

    Body fat percentage will be assessed using the deuterium dilution technique and/or bioelectrical impedance analysis or the bodpod

    Time frame: Screening, Visits 4 (day 373), 5 (day 429), 6 (day 485) and 7 (day 541)

  11. Waist circumference

    Waist circumference will be measured as an indicator of body fat distribution.

    Time frame: Screening, Visits 4 (day 373), 5 (day 429), 6 (day 485) and 7 (day 541)

  12. Hip circumference

    Hip circumference will be measured as an indicator of body fat distribution.

    Time frame: Screening, Visits 4 (day 373), 5 (day 429), 6 (day 485) and 7 (day 541)

  13. Liver function

    Liver function will be assessed by measuring alanine transaminase and aspartate transaminase enzymes.

    Time frame: Screening

  14. Gut inflammation

    Gut inflammation will be assessed by measuring gut integrity and inflammation biomarkers namely Intestinal fatty acid-binding protein (IFABP) and soluble cluster of differentiation 14 (sCD14).

    Time frame: Screening

  15. Menstruation intensity

    Menstruation intensity will be assessed using a self-administered health diary

    Time frame: Day 373 to day 541

  16. Haemoglobin

    Haemoglobin measurement will be compared between a point-of-care device (Hemocue) and an automated haematology analyser

    Time frame: Screening

  17. Oestradiol

    17-beta oestradiol will be measured on days 2, 7, 18 and 23 of the menstrual cycle. The day 2 sample will align with visit 4 or the next convenient scheduled visit.

    Time frame: Visit 4 (day 373), day 378, day 389 and day 394

  18. Progesterone

    Progesterone will be measured on days 2, 7, 18 and 23 of the menstrual cycle. The day 2 sample will align with visit 4 or the next convenient scheduled visit.

    Time frame: Visit 4 (day 373), day 378, day 389 and day 394

07

Study locations

1 of 1 sites recruiting
  • Esté Vorster Research Facility
    Potchefstroom, North West 2531, South Africa
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jun 2027, 23 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 23 months is close to that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2025
First posted
Jul 23, 2025
StartActual
Jul 24, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07081152
Lead sponsor
Linda Malan
Collaborators
King's College London, ETH Zurich (Switzerland)
Responsible party
Linda Malan (Prof, North-West University, South Africa) — Sponsor-investigator
First posted
Jul 23, 2025
Start date
Jul 24, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Mar 23, 2026

Study contacts

Mary Uyoga, PhD
Contact
44645104@mynwu.ac.za
+27 18 299 4237
Linda Malan, PhD
Contact
Linda.Malan@nwu.ac.za
+27 18 299 4237
Linda Malan, PhD
principal investigator · Centre of Excellence for Nutrition, North-West University
Mary Uyoga, PhD
principal investigator · Centre of Excellence for Nutrition, North-West University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion